Understanding the FDA Approval Process for ALK-Positive Drugs: When Will NVL-655 Be Available?

For those living with ALK-positive lung cancer, the search for new treatments feels like a race against time. When current therapies lose effectiveness, patients and their loved ones are left waiting for the next breakthrough. NVL-655, an experimental ALK inhibitor, is one of the most anticipated new treatments, designed specifically to overcome resistance mutations that develop after other ALK-targeted therapies.

Clinical TrialsKirk SmithMarch 29, 2025Clinical Trials, FDA, NVL-655